title: Phase II study of epirubicin in advanced soft tissue sarcoma.
abstract: Thirty-seven patients (pts) with previously untreated and measurable advanced soft tissue sarcoma entered this phase II study: 22 men and 15 women were included. Median age was 58 (range: 20-71). The starting dose of epirubicin was 100 mg/m2 IV bolus every 3 wks. In the case of minimal myelosuppression, the dose was increased by 10 mg/m2 to 130 mg/m2 (Mean dose per cycle: 105 mg/m2). Median cumulative dose of epirubicin administered was 445 mg/m2 (range: 200-1320 mg/m2). From 32 evaluable pts, one had a complete response (CR), 5 a partial response (PR), (CR + PR = 18.7% +/- 13.8%), 12 showed no change (37.5%) and 14 had progressive disease. The number of complete or partial responses observed was not modified by increasing the doses of epirubicin. Median time to progression was 4 months. From 32 pts evaluable for toxicity, hematologic toxicity at d 21 was mild. Non hematological toxicities consisted of nausea and vomiting in 74% of pts (WHO grade 3 = 5%), stomatitis in 12.2% (WHO grade 3 = 3%) and alopecia in 91% (WHO grade 2-3 = 72%). No cardiac dysfunction was recorded during the treatment, even though 7 patients received more than 800 mg/m2 of epirubicin (median: 850 mg/m2, range: 810-1320 mg/m2). The results of this study show that epirubicin is an active drug in advanced soft tissue sarcoma.
authors: Centre H Becquerel, Rouen, France.
authors: B
authors: B
authors: Chevallier
authors: P
authors: P
authors: Montcuquet
authors: T
authors: T
authors: Fachini
authors: B
authors: B
authors: Nguyen Bui
authors: P
authors: P
authors: Kerbrat
authors: P
authors: P
authors: Bastit
authors: M L
authors: ML
authors: Vo Van
mesh_terms: D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000627:therapeutic use; D004341:Drug Evaluation / Q000379:methods*; D004354:Drug Screening Assays, Antitumor; D015251:Epirubicin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D015251:Epirubicin; D004317:Doxorubicin